Sao Paulo, March 19, 2026, 13:30 (BRT).
Banco Bradesco’s ADRs in the U.S. slipped roughly 1.4% to $3.48 Thursday afternoon. Over in Sao Paulo, its preferred shares had closed Wednesday at 18.63 reais, down 1.16%. Shares of Itaú Unibanco and Santander Brasil also dropped, so Bradesco stayed in line with the broader move among Brazilian banks, not diverging.
Timing is key here. On Wednesday, Brazil’s central bank trimmed the benchmark Selic rate to 14.75% from 15%. But the bank also bumped up its 2026 inflation outlook to 3.9%, up from 3.4%, and avoided laying out any hints about what’s next. Felipe Tavares at BGC Liquidez described the tone as “dovish.” Leonardo Costa from ASA Investments mentioned that if the Middle East shock fades, April could still see a deeper cut. Reuters
Bradesco’s 2026 targets pull that rate trajectory into focus. Back in February, the bank outlined ambitions for loan portfolio growth between 8.5% and 10.5% for this year, with net interest income after provisions expected to land somewhere from 42 billion to 48 billion reais. Management also stuck to its pledge to “expand profitability gradually and safely.” SEC
Bradesco, in a March 18 filing with the U.S. Securities and Exchange Commission, included its newly updated bylaws following shareholder meetings on March 10. The paperwork spelled out a capital increase of 6.67 billion reais, bumping the total to 93.77 billion reais by converting legal reserves—no fresh shares came out of it. Another tweak: the bylaws now explicitly allow profit sharing for management, as long as it stays within legal boundaries.
Bradesco shareholders signed off on the bank’s 2025 accounts, along with the plan to allocate 24.55 billion reais in net income. Out of that, 14.5 billion reais has been set aside for interest on shareholders’ equity—a common payout method in Brazil. Of this, 6.9 billion reais remains scheduled for payment by July 31. The meeting did not put forward any further distributions linked to 2025.
Next up: Bradesco has scheduled an extraordinary shareholders’ meeting for March 31 to vote on spinning off part of Bradseg. The move is part of the larger plan to shift the group’s health businesses over to Odontoprev. According to the bank, this would turn Odontoprev into the main consolidator for Bradesco’s healthcare operations, potentially streamlining the structure and boosting administrative efficiency.
Management isn’t pitching the reshuffle as just a tidy-up. Chairman Luiz Carlos Trabuco called the healthcare arm’s “scale, momentum and strategic relevance” out loud, while Chief Executive Marcelo Noronha floated the idea that the new company could see a market price tag “between R$40 billion and R$50 billion.” Mziq API
Still, things aren’t tidy. Oil shot higher when the Middle East conflict grew, global equities took a hit, and Brazil’s central bank called for “serenity and cautiousness” on rates ahead. Bradesco noted the March 10 bylaw revisions won’t kick in until the central bank says yes, and the healthcare overhaul remains subject to both shareholder and regulatory approval. Reuters
Investors seem content to hold for the moment. Bradesco offers a more defined corporate strategy on paper, and signs point to rates moving lower. Still, Thursday’s session showed shares remain tethered to broad macro risk, execution uncertainty, and whether the March 31 health vote actually delivers a clearer catalyst.
